279. Inhaled Sargramostim (rhu GM-CSF) Leads to Enhanced SARS-CoV-2 Virus-Specific Immune Response and Viral Clearance: Results of the Biomarker Cohort of a Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial in Non-Hospitalized Patients with COVID-19

BACKGROUND: Progression from mild to severe SARS-CoV-2 infection correlates with humoral and cellular immune signatures that adjust to a multiplying viral load. Enhancing immunity with host-directed therapy, such as sargramostim (yeast-derived, recombinant human granulocyte-macrophage colony-stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Ila, Garner, Fiona, Roychowdhury, Debasish F, Simms, Lorinda, Ahuja, Sanjeev, McManus, John L, Rock, Edwin P, Perez, Rodolfo, Bacchelli, Sandro, Paine, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676995/
http://dx.doi.org/10.1093/ofid/ofad500.351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676995/
http://dx.doi.org/10.1093/ofid/ofad500.351

Ejemplares similares